Meet Xeris Pharmaceuticals
Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.
Offering 2 proprietary formulation technologies
|Delivers highly concentrated, non-aqueous, ready-to-use formulations||✔||✔|
|Allows for subcutaneous (SC) and intramuscular (IM) delivery||✔||✔|
Can be administered using:
|Delivers peptides and small molecules||✔|
|Delivers large molecules (e.g., proteins, antibodies, vaccines)||✔|
XeriSol™ and XeriJect™ provide distinct advantages over existing formulations
Both XeriSol and XeriJect offer the opportunity to:
- Eliminate reconstitution
- Enable long-term room temperature stability
- Significantly reduce injection volume
- Eliminate the requirement for intravenous (IV) infusion
These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.
We are proud to announce that as of October 5, 2021,
Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc
are subsidiaries of Xeris Biopharma Holdings, Inc.
Not opening? Check to see you have pop-ups enabled or copy link below in a new window.https://ir.xerispharma.com/